Biotec Pharmacon appoints new CEO

Biotec Pharmacon ASA is pleased to announce that the company has hired Mr. Christian Jørgensen as the new CEO of Biotec Pharmacon ASA.

Christian has a MBA from INSEAD and MSc. Econ. from the University of Copenhagen. He has extensive background from the global healthcare industry, with positions as General Manager for Baxter Healthcare in Western Europe, Executive Vice President at Coloplast and President for Hill-Rom’s European business.

Christian will commence in his position on 2 October 2017 and Svein Lien will resign from his position as of the same date, and become available as a consultant for a period going forward.

“After Svein decided to resign as a CEO, the Board has thoroughly searched the Norwegian and the international market for suitable candidates to take the helm of Biotec. We are therefore very pleased to announce Christian Jørgensen, who is a very experienced international leader of several biotech companies, as the new CEO. We are confident that Christian will preserve and develop Biotec Phamacon’s commercial opportunities further and to be a key driver of strategic initiatives that will enhance shareholder value going forward. I would also like to use this opportunity to thank Svein Lien for his efforts to build Biotec Pharmacon to become a valued player in the advanced enzyme business and to build a broad platform of opportunities with the beta-glucan technology. ”, says Erik Thorsen, Chairman of the Board in Biotec Pharmacon ASA.